TABLE 1

Characteristics of Children With IPD in Pre-PCV13 and Post-PCV13 Periods

Pre-PCV13, n (%) (n = 168)Post-PCV13, n (%) (n = 85)P
Patient characteristics
 Age group.810
  <2 mo7 (4.2)2 (2.4)
  2–23 mo89 (53.0)48 (56.5)
  2–5 y72 (42.9)35 (41.2)
 Male93 (55.4)47 (55.3)1.000
 Race.975
  White79 (47.0)35 (41.2)
  Black18 (10.7)11 (12.9)
  Asian7 (4.2)4 (4.7)
  American Indian1 (0.6)0 (0)
  Other18 (10.7)7 (8.2)
  Unknown45 (26.8)28 (32.9)
 Comorbidity33 (19.6)20 (23.5).510
 PCV immunization1.000
  Up to date100 (59.5)50 (58.8)
 PPV23 immunization.552
  Received3 (1.8)0 (0)
Clinical features
 Site of isolation.682
  Cerebrospinal fluid2 (1.2)1 (1.2)
  Blood159 (94.6)78 (91.8)
  Pleural fluid2 (1.2)3 (3.5)
  Synovial fluid1 (0.6)0 (0)
  Pancreatic fluid1 (0.6)0 (0)
 Symptoms72 (42.9)46 (54.1).109
  Fever49 (29.2)34 (40).090
Microbiologic features
 PCV7 serotype
  18C1 (0.6)1 (1.2)1.000
  19F1 (0.6)0 (0)1.000
 PCV13 serotype
  30 (0)2 (2.4)1.000
  7F16 (9.5)8 (9.4).823
  19A67 (39.9)17 (20)<.0001
  NVT40 (23.8)47 (55.3)<.0001
Outcomes
 Hospitalized85 (50.6)49 (57.6).333
 Length of hospital stay, median [range, d]3 [0–42]4 [0–17].210
 Readmitted after discharge7 (4.2)2 (2.4).722
 Mortality6 (3.6)3 (3.5)1.000
  • PPV23, 23-valent pneumococcal polysaccharide vaccine.